An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02596035 |
Recruitment Status :
Completed
First Posted : November 4, 2015
Results First Posted : August 28, 2019
Last Update Posted : October 27, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Cell Carcinoma | Drug: Nivolumab | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 197 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) |
Actual Study Start Date : | January 8, 2016 |
Actual Primary Completion Date : | March 19, 2018 |
Actual Study Completion Date : | May 24, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Nivolumab
Nivolumab dose as specified
|
Drug: Nivolumab
Other Name: Opdivo |
- Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Immune Mediated Adverse Events (IMAEs) [ Time Frame: Up to 100 days of the last dose of study drug (Approximately 2 years) ]IMAEs were tabulated using worst grade per Common Terminology Criteria for Adverse Events, National Cancer Institute (NCI CTCAE) Version 4.0 criteria by system organ class and MedDRA version 20.1 preferred term.
- Median Time to Onset of High Grade (Grade 3-5) Immune Mediated Adverse Events [ Time Frame: Up to 100 days of the last dose of study drug (Approximately 10 months up to 26 months) ]Time to onset was calculated from first dosing date to the event onset date. If a participant never experienced the given AE, the participant will be censored at the last contact date.
- Median Time to Resolution of High Grade (Grade 3-5) Immune Mediated Adverse Events [ Time Frame: From onset of grade 3-5 IMAEs to resolution of IMAEs (Approximately 4 years and 7 months) ]Time-to resolution of grade 3-5 AE was defined as the longest time from onset to complete resolution or improvement to the grade at baseline among all clustered select AEs in the category experienced by the participant. Events which worsened into grade 5 events (death) or have a resolution date equal to the date of death are considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be censored to the last known date alive.
- Percentage of Participants Who Receive Immune Modulating Medication for the Immune-Mediated Event (Any Grade) [ Time Frame: Up to 100 days of the last dose of study drug (Approximately 3 years and 2 months) ]Immune modulating medication includes corticosteroids, infliximab, cyclophosphamide, Intravenous immunoglobulin (IVIG), and mycophenolate mofetil
- Percentage of Participants Who Receive More Than Equal to (>=) 40 mg Prednisone Equivalents for the Immune-Mediated Event [ Time Frame: Up to 100 days of the last dose of study drug (Approximately 3 years and 2 months) ]Immune modulating medication includes corticosteroids, infliximab, cyclophosphamide, Intravenous immunoglobulin (IVIG), and mycophenolate mofetil
- Total Duration of All Immune Modulating Medications Given for the Immune-Mediated Event [ Time Frame: From the initiation of Immune modulating medication to discontinuation (approximately 4 years and 9 months).) ]Immune modulating medication includes corticosteroids, infliximab, cyclophosphamide, Intravenous immunoglobulin (IVIG), and mycophenolate mofetil.
- Percentage of Participants With a Resolution of IMAEs After Initiating Immune Modulating Medication [ Time Frame: Up to 100 days of the last dose of study drug (Approximately 2 years) ]Percentage of participants with a resolution of IMAEs after initiating immune modulating medication.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Advanced or Metastatic renal cell carcinoma (RCC)
-
Predominant clear cell histology:
- At least 1 but no more than 2 prior systemic anti vascular endothelial growth factor (anti-VEGF) treatments
- No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting
- Subjects with prior treatment with a mechanistic target of rapamycin (mTOR) are eligible
- Non-clear cell histology: 0-3 prior systemic therapies and may include mTOR inhibitor
- Brain metastases allowed if asymptomatic, without edema, and not receiving corticosteroids or radiation
- Performance Status (PS): ≥ 70% Karnofsky Performance Scale (KPS)
- All Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic scores allowed
Exclusion Criteria:
- Subjects with any active autoimmune disease or a history of known autoimmune disease
- History of severe hypersensitivity reaction to other monoclonal antibodies
- Prior malignancy, active within the last 3 years, except for locally curable cancers which have been apparently cured
- Known HIV or AIDS-related illness
- Any positive tests for Hepatitis B or Hepatitis C virus indicating acute or chronic infection
Other protocol-defined inclusion/exclusion criteria apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02596035
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Documents provided by Bristol-Myers Squibb:
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT02596035 |
Other Study ID Numbers: |
CA209-374 2015-003286-28 ( EudraCT Number ) |
First Posted: | November 4, 2015 Key Record Dates |
Results First Posted: | August 28, 2019 |
Last Update Posted: | October 27, 2022 |
Last Verified: | October 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases |
Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases Nivolumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |